Autonomic Nervous System Drugs Practice Questions

Q: Which of the following is the prototypical sympathomimetic agent with both alpha and beta-adrenergic activity?

Epinephrine. ***Epinephrine*** - Epinephrine (adrenaline) is a potent direct-acting **sympathomimetic** that stimulates both **alpha and beta-adrenergic receptors**. - Its diverse effects on the cardiovascular, respiratory, and other systems make it the prototypical agent for demonstrating both receptor activities. *Norepinephrine* - While norepinephrine (noradrenaline) also acts on **alpha and beta-1 receptors**, its affinity for **beta-2 receptors** is significantly lower than epinephrine. - This results in a predominant effect on **vasoconstriction** and cardiac contractility rather than bronchodilation or peripheral vasodilation. *Isoproterenol* - Isoproterenol is a **non-selective beta-adrenergic agonist**, meaning it primarily stimulates **beta-1 and beta-2 receptors**. - It has minimal or no activity at **alpha-adrenergic receptors**, differentiating it from epinephrine's mixed activity. *Dopamine* - Dopamine's effects are **dose-dependent**; at low doses, it primarily stimulates **dopamine receptors** and at moderate doses, it activates **beta-1 receptors**. - At high doses, it can stimulate **alpha-adrenergic receptors**, but its primary and distinguishing characteristic is its agonism at **dopamine receptors**, which epinephrine does not share.

Q: What is the best drug for open-angle glaucoma?

Latanoprost. Latanoprost - Latanoprost is a prostaglandin analog and is often considered a first-line treatment for open-angle glaucoma due to its efficacy in reducing intraocular pressure (IOP) and its once-daily dosing. - It works by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby lowering IOP. Pilocarpine - Pilocarpine is a cholinergic agonist that causes miosis and ciliary muscle contraction [3], increasing the outflow of aqueous humor through the trabecular meshwork [4]. - While effective, its side effects (e.g., accommodative spasm, miosis) [1] and more frequent dosing make it generally a second-line or third-line agent for long-term management compared to prostaglandins. Physostigmine - Physostigmine is an acetylcholinesterase inhibitor that indirectly increases acetylcholine, mimicking cholinergic stimulation. - Although it can lower IOP, it is generally not used for open-angle glaucoma due to significant side effects and the availability of safer, more effective alternatives [1]. Apraclonidine - Apraclonidine is an alpha-2 adrenergic agonist [2] used primarily for short-term control of IOP, especially before or after ocular surgery, or as an adjunct therapy. - Its efficacy as a long-term monotherapy for open-angle glaucoma is limited by tachyphylaxis and potential for significant systemic side effects with chronic use.

Q: Which of the following statements about dopamine is false?

Causes increase in GI Ischemia. ***Causes increase in GI Ischemia*** (FALSE Statement) - This statement is **incorrect and misleading** as dopamine does not primarily "cause increase in GI ischemia" - While dopamine at **higher doses** can cause **splanchnic vasoconstriction** via alpha-1 receptors, this is not characterized as "causing GI ischemia" in standard pharmacology - GI ischemia is a potential adverse effect in susceptible patients, but not a primary pharmacological effect or standard clinical description of dopamine *Positive inotropic* (TRUE Statement) - Dopamine is a **catecholamine** with dose-dependent effects; at **moderate doses (5-10 mcg/kg/min)**, it stimulates **beta-1 adrenergic receptors** in the heart - This beta-1 stimulation leads to increased **myocardial contractility** and **heart rate**, thus exerting a **positive inotropic effect** - This is a well-established therapeutic effect of dopamine *Improves renal perfusion* (TRUE Statement) - At **low doses (0.5-3 mcg/kg/min)**, dopamine selectively activates **dopamine-1 (D1) receptors** in the renal vasculature - This activation causes **renal vasodilation**, leading to increased **renal blood flow**, improved **glomerular filtration rate**, and enhanced **sodium excretion** - This "renal dose" effect is a classic pharmacological property of dopamine *Causes Vasoconstriction* (TRUE Statement) - At **high doses (>10 mcg/kg/min)**, dopamine primarily stimulates **alpha-1 adrenergic receptors** - This leads to generalized **vasoconstriction**, increasing **systemic vascular resistance** and **blood pressure** - This dose-dependent alpha effect is well-documented

Q: Guanethidine is used in the treatment of which of the following conditions?

Thyrotoxic ophthalmopathy. ***Thyrotoxic ophthalmopathy*** - Guanethidine is an **adrenergic neuron blocker** that can be used topically to reduce the sympathetic overactivity in the eye associated with thyrotoxicosis. - It helps alleviate symptoms like **retraction of the eyelids** and proptosis by blocking norepinephrine release from sympathetic nerve endings. *Ptosis* - **Ptosis** is primarily caused by weakness of the levator palpebrae superioris muscle or oculomotor nerve dysfunction, not sympathetic overactivity. - Guanethidine would not address the underlying muscular or neurologic deficit causing ptosis. *Bell's palsy* - **Bell's palsy** involves sudden, temporary weakness or paralysis of the muscles on one side of the face due to a dysfunction of the facial nerve. - Treatment typically involves corticosteroids and antivirals; guanethidine has no role in its management. *Horner's syndrome* - **Horner's syndrome** is characterized by miosis, ptosis, and anhidrosis, resulting from damage to the sympathetic nerve supply to the eye and face. - Guanethidine's mechanism of action would exacerbate, rather than treat, the existing sympathetic deficit in Horner's syndrome.

Q: Which of the following is not an alpha-blocker?

Atenolol. ***Atenolol*** - Atenolol is a **selective beta-1 adrenergic receptor blocker**, primarily used to treat hypertension, angina, and certain arrhythmias. - Its mechanism of action involves **blocking the effects of adrenaline** on the heart, leading to decreased heart rate and blood pressure, rather than affecting alpha receptors. *Indoramine* - Indoramine is an **alpha-1 adrenergic receptor blocker** used historically for hypertension. - It specifically **antagonizes alpha-1 receptors** in vascular smooth muscle, causing vasodilation. *Idazoxan* - Idazoxan is an **alpha-2 adrenergic receptor antagonist**, primarily used in research contexts. - It **blocks presynaptic alpha-2 receptors**, which can lead to an increase in norepinephrine release. *Prazosin* - Prazosin is a well-known **alpha-1 adrenergic receptor blocker** used to treat hypertension and benign prostatic hyperplasia (BPH). - It causes **vasodilation** by relaxing vascular smooth muscle, thus lowering blood pressure.

Q: What is the primary mechanism by which epinephrine reduces insulin secretion?

Predominantly through alpha action. ***Predominantly through alpha action*** - **Epinephrine** primarily reduces insulin secretion by stimulating **alpha-2 adrenergic receptors** on pancreatic beta cells. - Activation of these receptors leads to a decrease in **cAMP levels** and an inhibition of insulin release. *Predominantly through beta action* - **Beta-2 adrenergic receptor activation** on pancreatic beta cells typically **stimulates** insulin secretion, which is opposite to epinephrine's overall effect. - While epinephrine has both alpha and beta effects, the **alpha-2 inhibition** of insulin release predominates in this context. *Through both alpha and beta actions* - Although epinephrine exerts both alpha and beta effects, the **alpha-2 receptor-mediated inhibition** of insulin secretion is the dominant mechanism. - The **beta-2 receptor-mediated stimulation** of insulin release is overridden by the stronger inhibitory alpha-2 effect. *Through muscarinic receptors* - Muscarinic receptors are part of the **parasympathetic nervous system** and are involved in stimulating insulin secretion. - **Epinephrine** acts on adrenergic receptors, not muscarinic receptors, to influence insulin release.

Q: Which of the following is the MOST accurate statement about neostigmine?

It is a quaternary ammonium compound. ***It is a quaternary ammonium compound*** - **Neostigmine** has a **quaternary ammonium group**, making it highly polar and **ionized** at physiological pH. - This chemical structure **limits its ability to cross lipid barriers** such as the blood-brain barrier [1].*It undergoes some metabolism in the liver, but its primary route of elimination is hydrolysis by plasma cholinesterases* - This description is more characteristic of **succinylcholine**, a depolarizing neuromuscular blocker, which is rapidly hydrolyzed by **plasma cholinesterase (pseudocholinesterase)** [2]. - **Neostigmine** is primarily eliminated by **renal excretion** and hepatic metabolism, not predominantly by plasma cholinesterases.*It can cross the blood brain barrier* - Due to its **quaternary ammonium structure**, neostigmine is **ionized** and **highly polar**, significantly impeding its passage across the **blood-brain barrier** [1]. - This characteristic explains why it primarily exerts its effects peripherally, rather than centrally.*Prominent effect on cardiac muscle* - While **cholinergic agonists** can have effects on the heart (e.g., bradycardia), **neostigmine's primary therapeutic action** is on **skeletal muscle** (to reverse neuromuscular blockade) and the **gastrointestinal tract** (to treat ileus). - Its effects on cardiac muscle are typically **less prominent** compared to its effects on other effector organs at therapeutic doses for its main indications.

Q: Anticholinesterases are ineffective in which of the following conditions?

Cobra bite. ***Cobra bite*** - Cobra venom contains **α-neurotoxins** (e.g., α-bungarotoxin) that cause **postsynaptic nicotinic receptor blockade** at the neuromuscular junction. - The toxin binds with **high affinity and essentially irreversibly** to nicotinic acetylcholine receptors, preventing acetylcholine from binding. - Anticholinesterases are **ineffective** because increasing acetylcholine concentration cannot displace the tightly bound neurotoxin from the receptors. - This represents a **non-competitive, irreversible blockade** that cannot be overcome by increasing substrate concentration. *Belladonna poisoning* - Caused by **antimuscarinic alkaloids** (atropine, scopolamine) that block muscarinic acetylcholine receptors. - Anticholinesterases would increase acetylcholine levels at muscarinic sites but cannot effectively reverse severe antimuscarinic toxicity. - Treatment is primarily **supportive** with physostigmine in selected cases, but this is not standard management. *Postoperative ileus* - Anticholinesterases like **neostigmine are effective** in treating postoperative ileus by increasing acetylcholine at muscarinic receptors in the GI tract. - This enhances **gastrointestinal motility** and is a therapeutic use of anticholinesterases. *Carbamate poisoning* - Carbamates are **reversible anticholinesterase inhibitors** causing cholinergic excess. - Additional anticholinesterases would be **contraindicated** (not ineffective) as they would worsen the acetylcholine accumulation. - Treatment involves **atropine** to block muscarinic effects, not more anticholinesterases.

Q: Exocytic release of acetylcholine is blocked by

Botulinum toxin (blocks release of ACh). ***Botulinum toxin (blocks release of ACh)*** - **Botulinum toxin** acts by cleaving SNARE proteins (SNAP-25, synaptobrevin, syntaxin) which are essential for the fusion of synaptic vesicles with the presynaptic membrane, thereby **blocking exocytic release of acetylcholine**. - This blockage prevents the release of neurotransmitter from the nerve terminal, leading to muscle paralysis or reduced glandular secretions. *Hemicholinium (inhibits choline reuptake)* - **Hemicholinium** inhibits the high-affinity reuptake of **choline** into the presynaptic neuron, which is a crucial step in the synthesis of acetylcholine. - While it depletes acetylcholine stores over time, it does not directly block the immediate exocytic release of already synthesized acetylcholine. *Alphabungarotoxin (blocks ACh at receptors)* - **Alpha-bungarotoxin** is a potent antagonist that binds irreversibly and competitively to **nicotinic acetylcholine receptors (nAChR)** on the postsynaptic membrane. - Its action is postsynaptic, meaning it blocks the effect of acetylcholine once released, rather than preventing its release from the presynaptic terminal. *Vesamicol (interferes with ACh loading)* - **Vesamicol** inhibits the **vesicular acetylcholine transporter (VAChT)**, which is responsible for loading newly synthesized acetylcholine into synaptic vesicles. - By preventing the packaging of acetylcholine into vesicles, vesamicol reduces the amount of neurotransmitter available for release, but it does not directly block the exocytosis mechanism itself.

Q: Methacholine acts primarily at which receptor?

M3. ***M3*** - **Methacholine** is a non-selective muscarinic agonist that acts at all muscarinic receptors, but its **primary clinically relevant effects**, particularly in the airways (e.g., bronchoconstriction in asthma challenge tests), are mediated through **M3 receptors**. - **M3 receptors** are Gq-coupled and lead to **smooth muscle contraction**, glandular secretion, and vasodilation via nitric oxide release. *M1* - **M1 receptors** are primarily found in the central nervous system and autonomic ganglia, playing a role in **neuronal excitation** and **autonomic transmission**. - While methacholine can activate M1 receptors, this is not its predominant site of action for clinical uses. *M2* - **M2 receptors** are found in the heart and are Gi-coupled, leading to a **decrease in heart rate** and contractility. - While methacholine acts on M2 receptors, its most notable effects (like bronchoconstriction) are not primarily mediated through M2. *M4* - **M4 receptors** are primarily located in the central nervous system, where they modulate neurotransmitter release and contribute to **motor control** and cognition. - Methacholine has some affinity for M4, but it is not the primary receptor responsible for its clinically relevant effects.

Question 1

Which of the following is the prototypical sympathomimetic agent with both alpha and beta-adrenergic activity?

Accepted Answer

Epinephrine

Answer

Isoproterenol

Answer

Norepinephrine

Answer

Dopamine

Question 2

What is the best drug for open-angle glaucoma?

Accepted Answer

Latanoprost

Answer

Pilocarpine

Answer

Physostigmine

Answer

Apraclonidine

Question 3

Which of the following statements about dopamine is false?

Accepted Answer

Causes increase in GI Ischemia

Answer

Improves renal perfusion

Answer

Causes Vasoconstriction

Answer

Positive ionotropic

Question 4

Guanethidine is used in the treatment of which of the following conditions?

Accepted Answer

Thyrotoxic ophthalmopathy

Answer

Ptosis

Answer

Bell's palsy

Answer

Horner's syndrome

Question 5

Which of the following is not an alpha-blocker?

Accepted Answer

Atenolol

Answer

Indoramine

Answer

Idazoxan

Answer

Prazosin

Question 6

What is the primary mechanism by which epinephrine reduces insulin secretion?

Accepted Answer

Predominantly through alpha action

Answer

Predominantly through beta action

Answer

Through both alpha and beta actions

Answer

Through muscarinic receptors

Question 7

Which of the following is the MOST accurate statement about neostigmine?

Accepted Answer

It is a quaternary ammonium compound

Answer

It undergoes some metabolism in the liver, but its primary route of elimination is hydrolysis by plasma cholinesterases

Answer

It can cross the blood brain barrier

Answer

Prominent effect on cardiac muscle

Question 8

Anticholinesterases are ineffective in which of the following conditions?

Accepted Answer

Cobra bite

Answer

Belladonna poisoning

Answer

Postoperative ileus

Answer

Carbamate poisoning

Question 9

Exocytic release of acetylcholine is blocked by

Accepted Answer

Botulinum toxin (blocks release of ACh)

Answer

Hemicholinium (inhibits choline reuptake)

Answer

Alphabungarotoxin (blocks ACh at receptors)

Answer

Vesamicol (interferes with ACh loading)

Question 10

Methacholine acts primarily at which receptor?

Accepted Answer

M3

Answer

M1

Answer

M2

Answer

M4

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?